Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0063

Medical education · Dr. Liam Quinn

07 Jun 2026 · Virtual · Dr. Liam Quinn, Royal Marsden · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0063—

Capture insight from this engagement

Location: Vall d'Hebron
Therapeutic area: Oncology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Comparator checkpoint monotherapy
Duration of response

Scientific content used

irAE management guide

Questions raised

What is the evidence for re-challenge with checkpoint inhibitors after progression on vantrelimab?
Is there subgroup data for patients with untreated brain metastases?

Notes

Medical education with radiation oncologist at Vall d'Hebron. Discussed comparator checkpoint monotherapy, duration of response.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Send publication reprint

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 3
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0063

Audit history (0)

All create, update and approval events for this record

No audit events in sample data